First-in-Humans Study
First-in-human studies administer an experimental medicine or treatment to a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects. (NIH)
First-in-human studies administer an experimental medicine or treatment to a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects. (NIH)
Support Provided by AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Genentech, Merck, and Sanofi.
